SpringWorks Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SWTX research report →
Companywww.springworkstx.com
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors.
- CEO
- Saqib Islam
- IPO
- 2019
- Employees
- 368
- HQ
- Stamford, CT, US
Price Chart
Valuation
- Market Cap
- $3.54B
- P/E
- -21.93
- P/S
- 32.00
- P/B
- 8.43
- EV/EBITDA
- -21.45
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.79%
- Op Margin
- -146.32%
- Net Margin
- -145.06%
- ROE
- -35.72%
- ROIC
- -38.11%
Growth & Income
- Revenue
- $191.59M · 3417.33%
- Net Income
- $-258,131,000 · 20.60%
- EPS
- $-3.48 · 32.43%
- Op Income
- $-278,131,000
- FCF YoY
- 21.78%
Performance & Tape
- 52W High
- $62.00
- 52W Low
- $28.21
- 50D MA
- $45.88
- 200D MA
- $41.19
- Beta
- 0.70
- Avg Volume
- 5.85M
Get TickerSpark's AI analysis on SWTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 25 | Edris Badreddin | sell | 33,778 |
| Jul 1, 25 | Edris Badreddin | sell | 3,868 |
| Jul 1, 25 | Edris Badreddin | sell | 149,470 |
| Jul 1, 25 | Edris Badreddin | sell | 100,000 |
| Jul 1, 25 | Edris Badreddin | sell | 240,000 |
| Jul 1, 25 | Edris Badreddin | sell | 169,712 |
| Jul 1, 25 | Edris Badreddin | sell | 120,000 |
| Jul 1, 25 | Edris Badreddin | sell | 78,960 |
| Jul 1, 25 | LYNCH DANIEL | sell | 29,983 |
| Jul 1, 25 | LYNCH DANIEL | sell | 7,464 |
Our SWTX Coverage
We haven't published any research on SWTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SWTX Report →